Regulatory Europe Approves Novo Nordisk's Ozempic for Reducing Kidney Disease...

Europe Approves Novo Nordisk’s Ozempic for Reducing Kidney Disease Risk

-

Danish pharmaceutical company Novo Nordisk has received approval from the European Medicines Agency (EMA) to expand the labeling of its diabetes medication Ozempic. The updated label will now include the prevention of chronic kidney disease (CKD)-related events in adults with type 2 diabetes. This decision follows positive results from the phase III FLOW trial, which demonstrated Ozempic’s ability to slow CKD progression and reduce associated risks.

The FLOW trial, a randomized controlled study comparing Ozempic to placebo, was terminated early due to its strong efficacy. The results showed that Ozempic reduced all-cause mortality by 20% in patients with CKD compared to placebo. Additionally, major kidney disease events were reduced by 24%, and cardiovascular events decreased by 18% in the treated group. These findings suggest that patients taking Ozempic benefit not only from improved glycemic control but also from reduced risks of CKD and cardiovascular complications.
Diabetes is a leading cause of kidney failure, as persistently high blood sugar gradually damages blood vessels, according to the National Kidney Foundation. Ozempic addresses this dual challenge by targeting both glycemic control and the progression of kidney disease, making it a significant advancement in the treatment of type 2 diabetes.
Novo Nordisk is also pursuing a similar label expansion in the United States, with a decision from the FDA anticipated in the first quarter of 2025. Such developments are expected to solidify Ozempic’s position in the rapidly growing GLP-1 drug market, which is projected to reach $111 billion by 2033 as new therapeutic uses emerge for these medications beyond diabetes and obesity.
The competitive landscape in this market continues to intensify. Novo Nordisk has its own TREASURE-CKD trial underway for Zepbound (tirzepatide), a GIP/GLP-1 receptor agonist, aimed at treating obesity and CKD with or without type 2 diabetes. This trial is expected to conclude by mid-2026.

With the EMA’s approval, Ozempic becomes a crucial asset for Novo Nordisk in addressing diabetes and kidney disease, improving the quality of life for millions of patients worldwide.

Life Sciences Voice Logo mobile
+ posts

Latest news

Sionna Therapeutics Targets $156 Million in IPO to Advance Cystic Fibrosis Research

Sionna Therapeutics, a biotechnology firm headquartered in Waltham, Massachusetts, is preparing to raise up to $156 million through an...

AdvanCell Bags $112M in Series C Funding For Alpha Radiopharma Trial

AdvanCell has raised $112 million in a Series C fundraising round supported by Sanofi Ventures. The Australian radiopharmaceutical firm...

Atalanta Therapeutics Secures $97 Million to Advance siRNA Therapies for Neurological Disorders

Atalanta Therapeutics has raised $97 million in a successful Series B financing round, which will support the initiation of...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you